PET/CT

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

Retrieved on: 
Friday, March 22, 2024
PET/CT, Contract research organization, Biotechnology, Sarcoidosis, Disease, Patient safety, Patient, Tablet, Spirometry, Messenger, Quality of life, Biology, Royal, Fibrosis, Clinical trial, European, Arrest, Safety, Pharmacokinetics, MOC, Phase, KITE, FDA, FVC, ECG, Granuloma, Pharmaceutical industry

The world's first administration of the chitotriosidase 1 (CHIT1) inhibitor (or placebo) to patient took place at the Royal Infirmary in Edinburgh.

Key Points: 
  • The world's first administration of the chitotriosidase 1 (CHIT1) inhibitor (or placebo) to patient took place at the Royal Infirmary in Edinburgh.
  • As part of the trial, patients will take a daily fixed dose of 25 mg OATD-01 or placebo tablets for 12 weeks.
  • Patient safety will be monitored regularly through laboratory tests, neurological examinations and ECG and spirometry.
  • The study will involve approximately 20-30 centres in the US, the European Union, Norway and the UK.

Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Retrieved on: 
Tuesday, April 2, 2024
Software, Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Technology, Clinical Trials, SMC, Safety, Lung cancer, Patient, BHCC, PET/CT, OTCQB, Cancer, MRI, NSCLC, GDT

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.

Key Points: 
  • Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.
  • Preliminary imaging results for this last patient in the first cohort, obtained six weeks after beginning treatment, show a favorable safety and tolerability profile, and promising early efficacy for the Deltacel™ treatment.
  • Additionally, the Deltacel-01 Safety Monitoring Committee (SMC) convened to analyze all preliminary patient data received to date and to determine the next phase of the trial.
  • This unanimous recommendation was based on encouraging preliminary data supporting Deltacel™ safety and tolerability, and evidence of anti-tumor activity.

GE HealthCare Announces the FDA Clearance of nCommand Lite by IONIC Health

Retrieved on: 
Monday, March 25, 2024
Mobile, Wireless, Technology, Medical Devices, FDA, Health Technology, Software, Hardware, Radiology, Health, Data Management, PET/CT, Lite, Patient, ASRT, Workflow, GE HealthCare, Society, Digital Solutions, Radiographer, Medical imaging

GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s nCommand Lite technology.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s nCommand Lite technology.
  • IONIC Health’s nCommand Lite includes multi-modality capabilities in support of magnetic resonance (MR), computed tomography (CT), and positron emission tomography/CT (PET/CT) scanning.
  • To further enhance its remote operations portfolio, GE HealthCare launched an FDA-cleared new version of Digital Expert Access and announced an exclusive distribution agreement with IONIC Health in November 2023.
  • “We are thrilled that our nCommand Lite solution, built on the three-year-strong nCommand platform from Brazil, is now cleared for use in the U.S.,” said José Leovigildo Coelho, CEO and co-founder of IONIC Health.

GE HealthCare and Hartford HealthCare Renew and Evolve 7-Year Collaboration to Advance Patient Care and Access in Connecticut

Retrieved on: 
Thursday, March 14, 2024
Technology, Hospitals, Health Technology, Other Health, Radiology, Health, Pharmaceutical, Data Management, Artificial Intelligence, Diagnosis, Deep learning, PET/CT, Head, Experiential learning, Algorithm, Longevity, MRI, X-ray, HHC, Anesthesia, OEC, Patient, Artificial intelligence, Acquisition, Mammography, Software, Critical care, GE HealthCare, Artifact, Multimedia, Nuclear medicine

The Care Alliance strives to assist Hartford HealthCare in increasing access to innovation while decreasing the total cost of care for patients.

Key Points: 
  • The Care Alliance strives to assist Hartford HealthCare in increasing access to innovation while decreasing the total cost of care for patients.
  • The collaboration will increase patients’ access to GE HealthCare’s most current imaging technology, and may provide shorter scan times, reduced waiting times for care, and enable clinicians to have greater accuracy in diagnostic assessments.
  • The agreement also includes GE HealthCare patient monitoring, anesthesia, maternal infant care and diagnostic cardiology technologies.
  • GE HealthCare and Hartford HealthCare will also execute build-in-place upgrades with some existing MRI, CT, PET/CT, and X-rays to refresh older systems with fewer construction costs and while minimizing waste, equipment downtime, and disruption to patient care.

CDL Nuclear Technologies Launches New Mobile Cardiac PET/CT Trailer

Retrieved on: 
Thursday, April 4, 2024
PET/CT, Trailer, Patient, PET, Hospital, Nature, CDL, Medicare, Physician, Medical imaging

WEXFORD, Pa., April 4, 2024 /PRNewswire/ -- CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer. This cutting-edge mobile solution is designed to revolutionize cardiac care by directly providing state-of-the-art cardiac PET/CT imaging services to medical facilities on their schedule.

Key Points: 
  • WEXFORD, Pa., April 4, 2024 /PRNewswire/ -- CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer.
  • This cutting-edge mobile solution is designed to revolutionize cardiac care by directly providing state-of-the-art cardiac PET/CT imaging services to medical facilities on their schedule.
  • Positioned as a low-risk, high-value option, the Mobile Cardiac PET/CT Trailer is aimed at enhancing cardiac programs across various medical facilities and practices.
  • The Mobile Cardiac PET/CT Trailer marks CDL Nuclear Technologies' third flexible solution, which ranges from complete end-to-end PET/CT build-outs to mobile, on-demand daily use Rubidium-82 radioisotope services.

Hoag First in World to Enroll Prostate Cancer Patients in Molecular Imaging & Therapy Clinical Trials

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, Molecular imaging, PET/CT, Prostate cancer, Patient, Prostate, Cancer, PSMA, Medical imaging

NEWPORT BEACH, Calif., April 2, 2024 /PRNewswire/ -- Hoag is the first site in the world to enroll patients in two clinical trials for prostate cancer staging and treatment.

Key Points: 
  • NEWPORT BEACH, Calif., April 2, 2024 /PRNewswire/ -- Hoag is the first site in the world to enroll patients in two clinical trials for prostate cancer staging and treatment.
  • One trial focuses on molecular imaging and the other on molecular therapy; both are poised to redefine the standard of care for patients with prostate cancer worldwide.
  • "The MIRROR trial aims to bridge the gap in prostate cancer management by evaluating the utility of Pylarify imaging in favorable intermediate prostate cancer," said Gary A. Ulaner, M.D., Ph.D., F.S.N.M.M.I., F.A.C.N.M., the James & Pamela Muzzy Endowed Chair in Molecular Imaging & Therapy at the Hoag Family Cancer Institute.
  • This offers patients at Hoag unique access to leading-edge prostate cancer imaging and therapy options that aren't yet available in most cancer centers.

RadNet Reports Fourth Quarter 2023 Results, Including Record Revenue and Adjusted EBITDA(1), Releases 2024 Financial Guidance and Forms a New Digital Health Reporting Segment

Retrieved on: 
Thursday, February 29, 2024
Cloud, Acquisition, Digital health, EBCD, LOS, AI, Investment, De novo, Growth, Imaging, Lung, Adjustment, Breast, Comprehensive income, Information technology, Mammography, RadNet, Google Images, Software, Artificial intelligence, MRI, PET/CT, Video game

Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “Record Revenue and Adjusted EBITDA(1) in the fourth quarter enabled us to exceed our 2023 full-year revised guidance ranges, ranges that were increased several times throughout 2023.

Key Points: 
  • Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “Record Revenue and Adjusted EBITDA(1) in the fourth quarter enabled us to exceed our 2023 full-year revised guidance ranges, ranges that were increased several times throughout 2023.
  • Adjusted EBITDA(1) margins in the Imaging Center segment improved in the fourth quarter of 2023 relative to 2022 by 30 basis points, from 16.1% to 16.4%.”
    “During 2023, we carefully managed liquidity and financial leverage.
  • Including our AI reporting segment, total company Revenue was $420.4 million in the fourth quarter of 2023, an increase of 9.5% from $383.9 million in last year’s fourth quarter.
  • For full-year 2023, RadNet reported Revenue from its Imaging Center reporting segment of $1,604 million and Adjusted EBITDA(1) Excluding Losses from the AI reporting segment of $245.1 million.

RadNet to Enter the Houston, Texas Market through Platform Acquisition of Houston Medical Imaging

Retrieved on: 
Tuesday, February 27, 2024
Acquisition, Radiology, MD, De novo, Mammography, RadNet, Houston Medical, MRI, PET/CT, Medical imaging

Upon closing the acquisition, which is anticipated to occur during the second quarter, 2024, RadNet will be entering its first new market since 2020.

Key Points: 
  • Upon closing the acquisition, which is anticipated to occur during the second quarter, 2024, RadNet will be entering its first new market since 2020.
  • The seven centers, once acquired, will continue to operate under the Houston Medical Imaging brand, and will offer multi-modality services, including MRI, CT, PET/CT, X-ray, ultrasound, mammography and other procedures.
  • We believe this initial acquisition forms a strong platform from which to grow a new core network for RadNet.
  • The Houston market exhibits many of the characteristics that have permitted us to be successful in other RadNet core geographies.

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Retrieved on: 
Tuesday, February 27, 2024
Cancer, Glomus tumor, MD, International Cancer Imaging Society, Society, Therapy, Peter, Patient, Radiopharmaceutical, Molecular imaging, MTIC, MBBS, Pancreatic cancer, Research, PET/CT, Prostate cancer, Medical imaging

“We are very excited to have Professor Hicks as the lead investigator for our MNPR-101-Zr clinical trial,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.

Key Points: 
  • “We are very excited to have Professor Hicks as the lead investigator for our MNPR-101-Zr clinical trial,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
  • In 2023, Professor Hicks received the Saul Hertz Award from the Society of Nuclear Medicine and Molecular Imaging for his lifetime contribution to radionuclide therapy.
  • “The preclinical data that Monopar announced on this past Thursday encourages us to translate this class of agents into the clinical domain.
  • MNPR-101-Zr is being developed for cancers with very high unmet medical need, such as pancreatic cancer and triple negative breast cancer,” said Professor Hicks.

Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

Retrieved on: 
Wednesday, February 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NSCLC, OTCQB, Neoplasm, Progression-free survival, Metabolism, BHCC, Principal, Metastasis, Lung cancer, Safety, Patient, PET/CT, Pharmaceutical industry

This patient, who was treated at the Beverly Hills Cancer Center (BHCC), continues to do well two months following treatment.

Key Points: 
  • This patient, who was treated at the Beverly Hills Cancer Center (BHCC), continues to do well two months following treatment.
  • “We are proud and excited to report these highly promising early results showing tumor reduction in a patient population that has few treatment options available.
  • Kiromic also reports that the second patient in the Deltacel-01 clinical trial has received the second and final infusion of Deltacel.
  • The Deltacel-01 clinical trial is expected to start enrolling patients at two additional clinical trial sites in the first half of the year.